Scolaris Content Display Scolaris Content Display

Productos biológicos, colchicina, corticosteroides, inmunosupresores e interferón alfa para el síndrome neuro‐Behçet

Collapse all Expand all

References

References to studies excluded from this review

Akman‐Demir 1996 {published data only}

Akman‐Demir G, Baykan‐Kurt B, Serdaroǧlu P, Gürvit H, Yurdakul S, Yazici H, et al. Seven‐year follow‐up of neurologic involvement in Behçet syndrome. Archives of Neurology 1996;53(7):691‐4.

Benamour 2006 {published data only}

Benamour S, Naji T, Alaoui FZ, El‐Kabli H, El‐Aidouni S. Neurological involvement in Behçet's disease, 154 cases from a cohort of 925 patients and review of the literature [Manifestations neurologiques de la maladie de Behçet]. Revue Neurologique 2006;162(11):1084‐90.

Borhani Haghighi 2011 {published data only}

Borhani Haghighi A, Sarhadi S, Farahangiz S. MRI findings of neuro‐Behcet's disease. Clinical Rheumatology 2011;30(6):765‐70.

Desbois 2012 {published data only}

Desbois AC, Wechsler B, Resche‐Rigon M, Piette JC, Huong Dle T, Amoura Z, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis and Rheumatism 2012;64(8):2753‐60.

Dutra 2011 {published data only}

Dutra LA, Braga‐Neto P, Pedroso JL, Guedes Bde V, de Souza LT, Gonçalves CR, et al. Epilepsy and Behçet's disease: cortical and hippocampal involvement in Brazilian patients. Journal of the Neurological Sciences 2011;309(1‐2):1‐4.

Essaadouni 2010 {published data only}

Essaadouni L, Jaafari H, Abouzaid CH, Kissani N. Neurological involvement in Behçet's disease: evaluation of 67 patients [Les manifestations neurologiques de la maladie de Behçet: étude de 67 patients]. Revue Neurologique 2010;166(8‐9):727‐33.

Farah 1998 {published data only}

Farah S, Al‐Shubaili A, Montaser A, Hussein JM, Malaviya AN, Mukhtar M, et al. Behçet's syndrome: a report of 41 patients with emphasis on neurological manifestations. Journal of Neurology, Neurosurgery, and Psychiatry 1998;64(3):382‐4.

Ideguchi 2010 {published data only}

Ideguchi H, Suda A, Takeno M, Kirino Y, Ihata A, Ueda A, et al. Neurological manifestations of Behçet's disease in Japan: a study of 54 patients. Journal of Neurology 2010;257(6):1012‐20.

Krupa 2011 {published data only}

Krupa B, Cimaz R, Ozen S, Fischbach M, Cochat P, Koné‐Paut I. Pediatric Behcet's disease and thromboses. Journal of Rheumatology 2011;38(2):387‐90.

Saadoun 2009 {published data only}

Saadoun D, Wechsler B, Resche‐Rigon M, Trad S, Le Thi Huong D, Sbai A, et al. Cerebral venous thrombosis in Behçet's disease. Arthritis and Rheumatism 2009;61(4):518‐26.

Sbai 2003 {published data only}

Sbai A, Wechsler B, Duhaut P, Du‐Boutin LT, Amoura Z, Cacoub P, et al. Neuro‐Behçet's disease (isolated cerebral thrombophlebitis excluded). Clinical pattern, prognostic factors, treatment and long term follow‐up. Advances in Experimental Medicine and Biology 2003;528:371‐6.

Serdaroğlu 1989 {published data only}

Serdaroğlu P, Yazici H, Ozdemir C, Yurdakul S, Bahar S, Aktin E. Neurologic involvement in Behçet's syndrome. A prospective study. Archives of Neurology 1989;46(3):265‐9.

Tohmé 2009 {published data only}

Tohmé A, Koussa S, Haddad‐Zébouni S, El‐Rassi B, Ghayad E. Neurological manifestations of Behcet's disease: 22 cases among 170 patients [Étude de 22 observations de neuroBehçet dans une série de 170 maladies de Behçet]. Presse Médicale 2009;38(5):701‐9.

Wechsler 1992 {published data only}

Wechsler B, Vidailhet M, Piette JC, Bousser MG, Dell Isola B, Blétry O, et al. Cerebral venous thrombosis in Behçet's disease: clinical study and long‐term follow‐up of 25 cases. Neurology 1992;42(3 Pt 1):614‐8.

Whallett 1999 {published data only}

Whallett AJ, Thurairajan G, Hamburger J, Palmer RG, Murray PI. Behçet's syndrome: a multidisciplinary approach to clinical care. QJM: monthly journal of the Association of Physicians 1999;92(12):727‐40.

Yesilot 2007 {published data only}

Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman‐Demir G. Clinical characteristics and course of spinal cord involvement in Behçet's disease. European Journal of Neurology 2007;14(7):729‐37.

Yesilot 2009 {published data only}

Yesilot N, Bahar S, Yilmazer S, Mutlu M, Kurtuncu M, Tuncay R, et al. Cerebral venous thrombosis in Behçet's disease compared to those associated with other etiologies. Journal of Neurology 2009;256(7):1134‐42.

Additional references

Jump to:

Abbas 2001

Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System. Philadelphia: W. B. Saunders Co, 2001.

Accardo‐Palumbo 2010

Accardo‐Palumbo A, Giardina AR, Ciccia F, Ferrante A, Principato A, Impastato R, et al. Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behcet’s disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity. Arthritis Research & Therapy 2010;12(3):109.

Ait Ben Haddou 2012

Ait Ben Haddou EH, Imounan F, Regragui W, Mouti O, Benchakroune N, Abouqal R, et al. Neurological manifestations of Behçet's disease: evaluation of 40 patients treated by cyclophosphamide. Revue Neurologique (Paris) 2012;168(4):344‐9.

Akman‐Demir 1999

Akman‐Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain 1999;122:2171‐81.

Akman‐Demir 2008

Akman‐Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal‐Tutkun I. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement?. Clinical and Experimental Rheumatology 2008;26(4 Suppl 50):S84‐90.

Al‐Araji 2009

Al‐Araji A, Kidd DP. Neuro‐Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurology 2009;8(2):192‐204.

Al‐Fahad 1999

Al‐Fahad S, Al‐Araji A. Neuro‐Behcet's disease in Iraq: a study of 40 patients. Journal of the Neurology Sciences 1999;170:105‐11.

Alty 2007

Alty JE, Monaghan TM, Bamford JM. A patient with neuro‐Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade. Clinical Neurology and Neurosurgery 2007;109(3):279‐81.

Arida 2011

Arida A, Fragiadaki K, Giavri E, Sfikakis P. Anti‐TNF agents for Behcet’s disease: analysis of published data on 369 patients. Seminars in Arthritis and Rheumatism 2011;41(1):61‐70.

Berlit 2010

Berlit P. Diagnosis and treatment of cerebral vasculitis. Therapeutic Advances in Neurological Disorders 2010;3(1):29‐42.

Calamia 2009

Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behçet's disease in the US: a population‐based study. Arthritis and Rheumatism 2009;61:600‐4.

CTCAE 2003

Cancer Therapy Evaluation Program. Common terminology criteria for adverse event. www.ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3to2.pdf (accessed 4 March 2013).

Dalvi 2012

Dalvi SR, Yildirim R, Yazici Y. Behcet's Syndrome. Drugs 2012;72(17):2223‐41.

Davatchi 2010

Davatchi F, Shams H, Rezaipoor M, Sadeghi‐Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study). International Journal of Rheumatic Diseases 2010;13(3):246‐52.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Dubois 2011

Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. British Journal of Clinical Pharmacology 2011;71(5):639‐41.

Egger 1997

Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315:629‐34.

Fasano 2011

Fasano A, D'Agostino M, Caldarola G, Feliciani C, De Simone C. Infliximab monotherapy in neuro‐Behçet's disease: four year follow‐up in a long‐standing case resistant to conventional therapies. Journal of Neuroimmunology 2011;239(1‐2):105‐7.

Giardina 2011

Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard immunosuppressive drugs. Rheumatology International 2011;31(1):33‐7.

Gilworth 2004

Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD‐QoL: a quality of life measure specific to Behçet's disease. Journal of Rheumatology 2004;31(5):931‐7.

Gül 2012

Gül A, Ohno S. HLA‐B*51 and Behçet Disease. Ocular Immunology and Inflammation 2012;20(1):37‐43.

Hatemi 2008

Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Annals of the Rheumatic Diseases 2008;67:1656‐62.

Hatemi 2012

Hatemi G, Seyahi E, Fresko I, Hamuryudan V. Behçet's syndrome: a critical digest of the recent literature. Clinical Experimental Rheumatology 2012;30(3 Suppl 72):80‐9.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Hirohata 1998

Hirohata S, Suda H, Hashimoto T. Low‐dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. Journal of the Neurological Sciences 1998;159(2):181‐5.

ICBD 2013

International Team for the Revision of the International Criteria for Behçet's Disease (ITR‐ICBD), Davatchi F, Assaad‐Khalil S, Calamia KT, Crook JE, Sadeghi‐Abdollahi B, et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology 2014;28(3):338‐47. [DOI: 10.1111/jdv.12107.]

ISG 1990

International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;355:1078‐80.

Kalra 2014

Kalra S, Silman A, Akman‐Demir G, Bohlega S, Borhani‐Haghighi A, Constantinescu CS, et al. Diagnosis and management of neuro‐Behçet's disease: international consensus recommendations. Journal of Neurology 2014;261(9):1662‐76.

Kato 2001

Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clinical and Experimental Ophthalmology 2001;29(5):335‐6.

Keino 2011

Keino H, Watanabe T, Taki W, Okada AA. Effect of infliximab on gene expression profiling in Behcet’s disease. Investigative Ophthalmology and Visual Science 2011;52(10):7681‐6.

Kidd 1999

Kidd D, Steuer A, Denman AM, Rudge P. Neurological complications of Behcet's syndrome. Brain 1999;122:2183‐94.

Kikuchi 2003

Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro‐Behçet's disease. A follow‐up study for 4 years. Advances in Experimental Medicine and Biology 2003;528:575‐8.

Kose 2012

Kose O. Development of immunopathogenesis strategies to treat Behcet’s disease. Pathology Research International 2012 Apr 3 [Epub ahead of print].

Kotake 1999

Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999;106(3):586‐9.

Kural‐Seyahi 2003

Kural‐Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long‐term mortality and morbidity of Behçet syndrome: a 2‐decade outcome survey of 387 patients followed at a dedicated center. Medicine 2003;82(1):60‐76.

Kötter 2006

Kötter I, Günaydin I, Batra M, Vonthein R, Stübiger N, Fierlbeck G, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications‐‐results of a retrospective analysis of 117 cases. Clinical Rheumatology 2006;25(4):482‐6.

Leccese 2010

Leccese P, D'Angelo S, Angela P, Coniglio G, Olivieri I. Switching to adalimumab is effective in a case of neuro‐Behcet's disease refractory to infliximab. Clinical and Experimental Rheumatology 2010;28(4 Suppl 60):S102.

Mat 2006

Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan, Y, Uysal O, et al. A double‐blind trial of depot corticosteroids in Behcet’s syndrome. Rheumatology (Oxford, England) 2006;45:348‐52.

Nichols 2001

Nichols JC, Ince A, Akduman L, Mann ES. Interferon‐alpha 2a treatment of neuro‐Behcet disease. Journal of Neuro‐opthalmology 2001;21(2):109‐11.

O'Duffy 1984

O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behçet's disease. American Journal of Medicine 1984;76(1):75‐84.

Olivieri 2011

Olivieri I, Leccese P, D'Angelo S, Padula A, Nigro A, Palazzi C, er al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clinical and Experimental Rheumatology 2011;29(4 Suppl 67):S54‐7.

Pipitone 2008

Pipitone N, Olivieri I, Padula A, D'angelo S, Nigro A, Zuccoli G, Boiardi L, Salvarani C. Infliximab for the treatment of Neuro‐Behçet's disease: a cases eries and review of the literature. Arthritis and Rheumatism 2008;59(2):285‐90.

Reeves 2011

Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non‐randomized studies. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Review Manager 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Saenz 1998

Saenz A, Ausejo M, Shea B, Wells GA, Welch V, Tugwell P. Pharmacotherapy for Behcet's syndrome. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD001084]

Salvarani 2007

Salvarani C, Pipitone N, Catanoso MG, Cimino L, Tumiati B, Macchioni P, et al. Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of northern Italy: a seventeen‐year population‐based study. Arthritis and Rheumatism 2007;57:171‐8.

Sarwar 2005

Sarwar H, McGrath H, Espinoza LR. Successful treatment of long‐standing neuro‐Behçet's disease with infliximab. Journal of Rheumatology 2005;32(1):181‐3.

Schünemann 2011a

Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2011.

Schünemann 2011b

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, 2011.

Serdaroglu 1998

Serdaroglu P. Behçet’s disease and the nervous system. Journal of Neurology 1998;245:197‐205.

Shapiro 2012

Shapiro LS, Farrell J, Borhani Haghighi A. Tocilizumab treatment for neuro‐Behcet's disease, the first report. Clinical Neurology and Neurosurgery 2012;114(3):297‐8.

Shugaiv 2011

Shugaiv E, Tüzün E, Mutlu M, Kiyat‐Atamer A, Kurtuncu M, Akman‐Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro‐Behçet's disease with parenchymal involvement: presentation of four cases. Clinical and Experimental Rheumatology 2011;29(4 Suppl 67):S64‐7.

Singh 2011

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008794]

Siva 2001

Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behçet’s disease: diagnostic and prognostic aspects of neurological involvement. Journal of Neurology 2001;248:95‐103.

Sterne 2013

Sterne J, Higgins J, Reeves B. Extending the risk of bias tool to allow for assessment of non‐randomised studies, cluster‐randomised trials and cross‐over trials: a Cochrane methods innovation fund project. 21st Cochrane Colloquium, Quebec 19‐23 September 2013. Available from www.cochrane.org/features/2013‐cochrane‐colloquium.

Tugal‐Tutkun 2004

Tugal‐Tutkun I, Onal S, Altan‐Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. American Journal of Ophthalmology 2004;138:373‐80.

Uluduz 2011

Uluduz D, Kürtüncü M, Yapıcı Z, Seyahi E, Kasapçopur Ö, Özdoğan H, et al. Clinical characteristics of pediatric‐onset neuro‐Behçet disease. Neurology 2011;77(21):1900‐5.

Yazici 1980

Yazici H, Tuzun Y, Pazarli H, Yalcin B, Yurdakul S, Muftuoglu A. The combined use of HLA‐B5 and the pathergy test as diagnostic markers of Behçet's disease in Turkey. Journal of Rheumatology 1980;7(2):206‐10.

Yazici 2012

Yazici H, Ugurlu S, Seyahi E. Behçet syndrome: is it one condition?. Clinical Reviews in Allergy and Immunology 2012;43(3):275‐80.

Yazici 2014

Yazici H, Yazici Y. Criteria for Behçet's disease with reflections on all disease criteria. Journal of Autoimmunity 2014;48‐49:104‐7.

Characteristics of studies

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Akman‐Demir 1996

No control group.

Benamour 2006

No control group.

Borhani Haghighi 2011

No control group.

Desbois 2012

No control group.

Dutra 2011

No control group.

Essaadouni 2010

No control group.

Farah 1998

No control group.

Ideguchi 2010

No control group.

Krupa 2011

No control group.

Saadoun 2009

No control group.

Sbai 2003

Control group was not described with sufficient detail to allow assessment of potential 'confounding by indication'.

Serdaroğlu 1989

No control group.

Tohmé 2009

No control group.

Wechsler 1992

No control group.

Whallett 1999

No control group.

Yesilot 2007

No control group.

Yesilot 2009

No control group.

Flow diagram.
Figures and Tables -
Figure 1

Flow diagram.

Flow diagram (2).
Figures and Tables -
Figure 2

Flow diagram (2).